Interviews

Cristian Groenewegen

Chief Sustainability Officer and Managing Director of Benelux

2024-05-27

It's not enough to treat sustainability as a project to be rolled out, but rather about setting the right tone at the top and having it embraced as part of a company's DNA.

Renee Henze

Chief Sustainability Officer

IFF

2024-05-27

Innovation is at the heart of our sustainability efforts, and we're setting high standards for our new developments to ensure they surpass the sustainability benchmarks of their predecessors.

Al Beninati

CEO & President

PQ Corporation

2024-05-27

Our focus on innovation aims to enhance sustainability through circular economy contributions, CO2 reduction, and water impact improvements.

Wayne Yap

Executive Director

Association of Process Industry (ASPRI)

2024-05-27

Despite the challenges, these shifts towards greener solutions and the exploration of new technologies such as pyrolysis and bio-enzymatic materials signify a pivotal moment for the sector. The focus is increasingly on finding sustainable alternatives and navigating through this period of transition to secure a greener future for Singapore's petrochemical industry.

Miguel Fernández Alcalde

Chief Operating Officer (COO)

EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S.

2024-05-24

EMD Serono is intensely focused on several key therapeutic areas: neurology & immunology, fertility, oncology, and endocrinology. In neurology & immunology, particularly with diseases like multiple sclerosis (MS), we offer leading therapies that have been impactful for over two decades.

Paul Hawthorne

Executive VP and Chief Business Officer

Eisai Inc.

2024-05-24

We estimate that over 10 years cumulatively, the gradual adoption of LEQEMBI treatment at this pricing approach could give back about 60% of the potential positive social impact of several tens of billion dollars to the U.S. society.

Steve Fife

President & CEO

LifeVantage

2024-05-23

Modern lifestyles have diverged significantly from our bodies' original programming, creating a "perfect storm" for not only increased oxidative stress, but a decline in function, leading to numerous health issues. Our activation approach seeks to counteract this by reactivating our body's naturalprocesses, rather than merely supplementing or putting a bandaid on the real issue.

Seema Verma

EVP and GM

Oracle Health and Life Sciences

2024-05-23

In clinical trials, a traditionally costly and lengthy phase, Oracle is innovating by integrating vast amounts of data from our electronic health records, one of the largest in the world, and clinical trial management systems.

Steve Schaefer

President

Kyowa Kirin North America

2024-05-23

Focusing on the rare disease space enables us to target investments into meeting patients' needs with precision and empathy, often touching lives in profound ways. Our work to bring these innovations to patients extends beyond scientific achievement; it is about the real-world impact we hope to have on individuals and their families.

Trevor Martin

Co-Founder & CEO

Mammoth Biosciences

2024-05-22

We at Mammoth see the potential to address a wide range of genetic diseases, especially rare monogenic disorders. Our focus is on developing CRISPR-based therapies that can be administered in vivo and across different tissues, which is challenging yet critical for treating most genetic diseases.

Pagina 47 din 154